Amgen (AMGN) Beat Revenue Forecasts, Is The Stock Overvalued?
Amgen (AMGN) is back in focus after quarterly revenue of $8.62b surpassed analyst forecasts, with management pointing to double digit growth across 16 brands and reaffirming confidence in its long term outlook.
See our latest analysis for Amgen.
Against this backdrop, Amgen’s recent momentum has been firm. A 10.54% 90 day share price return and a 26.34% 1 year total shareholder return suggest investors are responding positively to earnings delivery and the company’s pipeline progress.
If you are reassessing your healthcare exposure after Amgen’s latest update, it could be a useful moment to look across the sector and search through 40 healthcare AI stocks
After a strong run that has taken Amgen shares to $376.04, the real tension now is between locking in exposure at today’s price or waiting for a pullback. How does the current valuation stack up against the fundamentals?
Most Popular Narrative: 4.5% Overvalued
On the latest narrative, Amgen’s fair value of $359.98 sits below the last close at $376.04, which puts that premium under close scrutiny.
The "Amgen 2027 Bull Case" relies on a classic top-line fallacy: assuming that macro obesity market growth and FDA's CNPV (Commissioner’s National Priority Voucher) tailwinds will automatically trigger a re-rating.
Here is the cold, data-driven reality:
Curious what underpins that fair value for Amgen, even with a premium price tag? The narrative leans on specific revenue paths, profit margins and a future earnings multiple that together define a very tight execution lane. Want to see which assumptions carry the most weight in that story and how they shape the projected return profile?
Result: Fair Value of $359.98 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, if Amgen delivers steadier revenue and profit growth than this narrative allows for, or if obesity assets scale faster than feared, the overvaluation case could weaken.
Find out about the key risks to this Amgen narrative.
Another View: Amgen Through the DCF Lens
Set against the narrative fair value of $359.98, the Simply Wall St DCF model points in the opposite direction, with an estimate of $686.36 per share. This suggests Amgen might be trading at a substantial discount to its modelled future cash flows. How should you weigh such a wide gap between story driven and cash flow driven views?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Amgen for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With mixed signals across Amgen’s valuation and growth narratives, are you ready to move past the headlines and inspect the details for yourself? To weigh the push and pull of those concerns and potential upsides, start by reviewing the 3 key rewards and 1 important warning sign.
Looking for more ideas beyond Amgen?
If Amgen has sharpened your interest in what else might be worth researching, do not stop here. Broaden your watchlist with a few focused idea lists.
- Spot potential value opportunities early by reviewing 49 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them.
- Strengthen your portfolio’s income stream by scanning 9 dividend fortresses built around companies offering higher yields with an eye on durability.
- Reduce portfolio shocks by concentrating on 79 resilient stocks with low risk scores where financial strength and lower risk profiles sit at the center of the selection.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com